Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists.
Rheumatol Int. 2021 Mar 8. doi: 10.1007/s00296-021-04824-4. Online ahead of print.
Rheumatol Int. 2021.
PMID: 33683393
In case of mild COVID-19, more than 50% of the respondents would continue pre-existing treatment with immunoglobulins (100%), hydroxychloroquine (94.2%), anakinra (79.2%) or canakinumab (72.5%), or tocilizumab (69.8%). Long-term corticosteroids would be reduced by 2 …
In case of mild COVID-19, more than 50% of the respondents would continue pre-existing treatment with immunoglobulins (100%), hydroxychloroq …